Cargando…

RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer

In metastatic colorectal cancer, RAS and BRAF mutations cause resistance to anti‐EGFR therapies, such as cetuximab. Heterogeneity in RAS and BRAF mutations might explain nonresponse in a subset of patients receiving cetuximab. Analyzing mutations in plasma‐derived circulating tumor DNA (ctDNA) could...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Helden, Erik J., Angus, Lindsay, Menke‐van der Houven van Oordt, C. Willemien, Heideman, Daniëlle A. M., Boon, Eline, van Es, Suzanne C., Radema, Sandra A., van Herpen, Carla M. L., de Groot, Derk Jan A., de Vries, Elisabeth G. E., Jansen, Maurice P. H. M., Sleijfer, Stefan, Verheul, Henk M. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822250/ https://www.ncbi.nlm.nih.gov/pubmed/31350822 http://dx.doi.org/10.1002/1878-0261.12550

Ejemplares similares

[(89)Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer
por: van Helden, E. J., et al.
Publicado: (2019)

Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer
por: Veluchamy, John Pradeep, et al.
Publicado: (2016)

Early (18)F-FDG PET/CT Evaluation Shows Heterogeneous Metabolic Responses to Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer
por: van Helden, Erik J., et al.
Publicado: (2016)

(89)Zr-cetuximab PET imaging in patients with advanced colorectal cancer
por: Menke-van der Houven van Oordt, Catharina Willemien, et al.
Publicado: (2015)

Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
por: van Helden, E. J., et al.
Publicado: (2017)

Successful Trastuzumab-Deruxtecan Rechallenge After Interstitial Lung Disease: A Case Report
por: de Weger, Vincent A., et al.
Publicado: (2023)

Methylated Cell-Free DNA Sequencing (MeD-seq) of LpnPI Digested Fragments to Identify Early Progression in Metastatic Renal Cell Carcinoma Patients on Watchful Waiting
por: Bos, Manouk K., et al.
Publicado: (2023)

Targeting BRAF and RAS in Colorectal Cancer
por: Bellio, Helene, et al.
Publicado: (2021)

Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
por: van Helden, E. J., et al.
Publicado: (2018)

Hepatosplenic Candidiasis Without Prior Documented Candidemia: An Underrecognized Diagnosis?
por: van Prehn, Joffrey, et al.
Publicado: (2017)

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS
por: Zuidervaart, W, et al.
Publicado: (2005)

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers
por: Nichols, Robert J., et al.
Publicado: (2018)

Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features
por: Lima Ferreira, Joana, et al.
Publicado: (2021)

Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
por: Goldinger, Simone M., et al.
Publicado: (2013)

First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis
por: Zheng, Bobo, et al.
Publicado: (2019)

Explainable artificial intelligence (XAI) in radiology and nuclear medicine: a literature review
por: de Vries, Bart M., et al.
Publicado: (2023)

Potential and pitfalls of (89)Zr-immuno-PET to assess target status: (89)Zr-trastuzumab as an example
por: Huisman, Marc C., et al.
Publicado: (2021)

Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology
por: Douma, Joeri A. J., et al.
Publicado: (2021)

Optimal imaging time points considering accuracy and precision of Patlak linearization for (89)Zr-immuno-PET: a simulation study
por: Wijngaarden, Jessica E., et al.
Publicado: (2022)

Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
por: Zhao, Yiqing, et al.
Publicado: (2021)

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016)

The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment
por: Ziranu, Pina, et al.
Publicado: (2021)

Systemic Therapy for Patients with HER2-Positive Breast Cancer and Brain Metastases: A Systematic Review and Meta-Analysis
por: Werter, Inge M., et al.
Publicado: (2022)

Structural insights into the BRAF monomer-to-dimer transition mediated by RAS binding
por: Martinez Fiesco, Juliana A., et al.
Publicado: (2022)

First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors
por: Menke-van der Houven van Oordt, C. Willemien, et al.
Publicado: (2016)

Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

Sorafenib administered using a high-dose, pulsatile regimen in patients with advanced solid malignancies: a phase I exposure escalation study
por: Mammatas, L. H., et al.
Publicado: (2020)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

RAF inhibitor PLX8394 selectively disrupts BRAF-dimers and RAS-independent BRAF mutant-driven signaling
por: Yao, Zhan, et al.
Publicado: (2018)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

The Mkk(3/6)-p38–Signaling Cascade Alters the Subcellular Distribution of Hnrnp A1 and Modulates Alternative Splicing Regulation
por: van der Houven van Oordt, Willemien, et al.
Publicado: (2000)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
por: Tsai, Hsiang-Lin, et al.
Publicado: (2023)

Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells
por: Arozarena, Imanol, et al.
Publicado: (2014)

Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients
por: Rosati, Gerardo, et al.
Publicado: (2021)

Unveiling the Domain-Specific and RAS Isoform-Specific Details of BRAF Regulation
por: Trebino, Tarah, et al.
Publicado: (2023)

Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib
por: De Pauw, Ines, et al.
Publicado: (2019)

Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report
por: Zelli, Veronica, et al.
Publicado: (2022)

BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS
por: Röck, Ruth, et al.
Publicado: (2019)

[(18)F]FES uptake in the pituitary gland and white matter of the brain
por: Iqbal, R., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aa9qr8sfi89oah12hp9sbtlrc5